PRODAPT
8.12.2021 13:23:10 CET | Business Wire | Press release
Prodapt , the leading consulting, technology & managed services provider to the Connectedness vertical, announced that it acquired SLR Dynamics , a UK-based company focused on digital engineering and automation services in the TMT industry. SLR Dynamics counts leading European and African telcos as their customers.
This is Prodapt’s second acquisition for the year following its acquisition of Silicon Valley-based Innovative Logic in August.
The acquisition of SLR Dynamics will strengthen Prodapt’s leadership position in the connectedness vertical. With the TMT industry accelerating digital transformation journeys using technologies like 5G, cloud, SDN/NFV, Edge Computing, IoT, and AI-ML, Prodapt’s acquisition of SLR Dynamics will help deliver enhanced value to its global customers.
“I am excited to welcome Salim and the SLR Dynamics team to the Prodapt family,” said Vedant Jhaver, Chairman and CEO, Prodapt. “The capabilities of SLR Dynamics in Cloud, Security, IoT and Product design will play an important role as Prodapt continues to become the preferred digital transformation partner to the enablers of hyper-connectivity,” he added.
This acquisition will also result in protecting 100+ jobs at SLR Dynamics. Over the next three years, Prodapt plans to grow the UK team by adding 400-500 employees with a plan to invest GBP 50 million.
Minister for Investment Gerry Grimstone said, “Prodapt’s decision to pick the UK as its investment destination of choice is a vote of confidence in the UK economy, and demonstrates the strength of UK and India’s bilateral relationship. We look forward to working together closely to bring high value jobs and economic growth to every corner of the UK as we build back stronger from the pandemic.”
Founded in 2009 to accelerate the adoption of a unified communications (UC) offering, SLR Dynamics has forged ahead and boasts an enviable client roster. SLR Dynamics have successfully executed multiple complex programs across UC, SDN/NFV, Cloud, Security, IoT and Mobile Money.
“ SLR Dynamics has always focused on building teams with deep domain knowledge and delivering high-quality services to our customers, ” said Salim Raza, CEO, SLR Dynamics. “Joining Prodapt will enable us to offer much deeper capabilities, take on larger engagements and deliver significantly enhanced value to our global telecom customers.”
About Prodapt: www.prodapt.com
Prodapt has a singular focus on the Connectedness vertical. Prodapt’s customers range from telecom operators, digital / multi-service providers (D/MSPs), technology and digital platform companies in the business of connectedness.
Prodapt builds, integrates, and operates solutions enabling next-generation technologies and innovations. Prodapt works with global leaders including AT&T, Verizon, CenturyLink, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, Deutsche Telekom among many others. Prodapt’s customers today help more than a billion people and five billion devices stay connected.
Prodapt has offices in North America, Europe, Latam, India, and Africa. It is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
About SLR Dynamics: slrdynamics.co.uk
Founded in 2009, SLR Dynamics works with a mission to help communications service providers (CSPs) become as agile and nimble as their “digital-born” competitors, by enabling them to accelerate bringing new services, features, and releases to market, in line with their customers’ expectations. SLR Dynamics brings expertise and experience in IT and networking to help tier-1 global companies adopt the very latest best practice in Automation, Cloud, Agile, DevOps, and Security.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005560/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom